3 Undervalued ETFs to Buy Before 2026

Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.

Zacks Investment Research • Dec 10, 2025

Pharma ETF (XPH) Hits a New 52-Week High

For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share.

Zacks Investment Research • Dec 9, 2025

US, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources say

Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.

Reuters • Dec 1, 2025

UK and US poised to agree zero-tariffs deal on pharmaceuticals, The Times says

The UK is poised to agree on a major pharmaceuticals deal with the U.S., which will mean zero import tariffs on pharmaceutical products into the U.S. and lead to an increase in NHS spending on medicines, The Times reported on Monday.

Reuters • Dec 1, 2025

UK and US agree zero-tariff pharmaceuticals deal

Agreement also calls for NHS to increase net price it pays for new medicines by 25%

The Guardian • Dec 1, 2025

US and UK agree zero-tariffs on pharmaceuticals

The US has agreed to spare the UK from threatened trade tariffs on pharmaceutical products.

Skynews • Dec 1, 2025

Britain will spend more on new medicines in exchange for avoiding tariffs on U.K. pharmaceutical exports to the U.S.

The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.

WSJ • Dec 1, 2025

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks Investment Research • Nov 28, 2025

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • Nov 27, 2025

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

Market Watch • Nov 18, 2025